Short term impacts of meglumine antimoniate treatment on kidney function in dogs with clinical leishmaniosis

González, M.A. Daza; Miró, Guadalupe; Rodríguez, María del Pilar García; Noguer, C. Rupérez; Arnold, Cristina Fragío

doi:10.1016/j.rvsc.2019.08.026

Cited by 9 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Miltefosine is better tolerated with regard to liver and kidney function. There is scarce information regarding possible toxicity of antimonials, and some authors have suggested possible kidney and liver secondary effects [71][72][73]. It is also true, however, that disease relapse occurs much earlier in dogs treated with miltefosine [73,74].…”

Section: Discussionmentioning

confidence: 99%

Latest trends in L. infantum infection in dogs in Spain, Part II: current clinical management and control according to a national survey of veterinary practitioners

et al. 2020

View full text Add to dashboard Cite

Background: Canine leishmaniosis (CanL) is a parasitic zoonotic disease, endemic in the Mediterranean basin including Spain. While knowledge about CanL, its management, treatment, prevention and control mounts, it remains unclear whether all clinical veterinarians follow the same international recommendations, such as those of the LeishVet group. This study was thus designed to assess recent trends in the clinical management of CanL in veterinary clinics across Spain through a questionnaire-based survey. Results were compared with those of a prior national multicenter questionnaire administered by our research team in 2005.

show abstract

Section: Discussionmentioning

confidence: 99%

Latest trends in L. infantum infection in dogs in Spain, Part II: current clinical management and control according to a national survey of veterinary practitioners

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The fact that CanL results in kidney disease in the more chronic stages makes it essential to choose non-nephrotoxic drugs during CanL treatment. Meglumine antimoniate therapies can induce kidney damage, even when used temporarily [ 26 , 27 ]. The alternative protocol is the combination of miltefosine plus allopurinol, which is considered safe because it has a hepatic metabolism.…”

Section: Discussionmentioning

confidence: 99%

“…The majority of the dogs (83.3%) had proteinuria, one of the first signs of renal impairments in dogs [ 26 , 32 ]. Dogs in both groups showed decreased proteinuria, suggesting that miltefosine alone or in combination with allopurinol did not impair renal function.…”

Section: Discussionmentioning

confidence: 99%

Monitoring of serum and urinary biomarkers during treatment of canine visceral leishmaniasis

et al. 2020

View full text Add to dashboard Cite

Background and Aim: Canine visceral leishmaniasis (CanL) has a broad spectrum of changes, with kidney disease being considered the main cause of mortality. Thus, this study aimed to monitor serum and urinary biomarkers in response to two short-term treatments for CanL. Materials and Methods: Thirty dogs with CanL were equally divided into two treatment groups and treated with either miltefosine (Group M) or miltefosine plus allopurinol (Group MA); the groups were evaluated before treatment and after 28 days of treatment. Physical exams were performed and hematimetric, biochemical, and urinary parameters, including urinary biomarkers cystatin C (CisC), lipocalin-2 (NGAL), and microalbuminuria, were measured. Results: Both treatments significantly reduced clinical scores (p<0.05), but only the MA group saw a reduction in the clinical-pathological score. The serum albumin and calcium levels increased significantly in the MA and M groups (p<0.05). Proteinuria and urinary density did not decrease significantly after the treatments. With regard to the biomarkers, CisC and microalbuminuria did not have any significant changes; however, NGAL was significantly reduced in the MA group (p<0.05). Conclusion: Both pharmacotherapeutic protocols promoted clinical and clinical-pathological improvements. In addition, miltefosine plus allopurinol proved to be a safe treatment due to the lack of changes detected in the monitored renal biomarkers. The treatment with miltefosine plus allopurinol proved to be the most effective, with more pronounced beneficial effects for canines with visceral leishmaniasis.

show abstract

“…2018, Daza González et al . 2019, IRIS 2019). Such dogs should then be closely followed up to determine the efficacy of treatment (Fig 1; Segev et al .…”

Section: What Is the Treatment Protocol For Kidney Disease Associatedmentioning

confidence: 99%

“…2016, Daza González et al . 2019). In dogs with UPC ≤ 3.0 and active leishmaniosis and hose that are sick or severely sick (Table 1; Paltrinieri et al .…”

Section: How Is Proteinuria Associated With Canl Treated?mentioning

confidence: 99%

Canine leishmaniosis and kidney disease: Q&A for an overall management in clinical practice

Roura

Cortadellas

Day

et al. 2020

J of Small Animal Practice

View full text Add to dashboard Cite

Short term impacts of meglumine antimoniate treatment on kidney function in dogs with clinical leishmaniosis

Cited by 9 publications

References 38 publications

Latest trends in L. infantum infection in dogs in Spain, Part II: current clinical management and control according to a national survey of veterinary practitioners

Latest trends in L. infantum infection in dogs in Spain, Part II: current clinical management and control according to a national survey of veterinary practitioners

Monitoring of serum and urinary biomarkers during treatment of canine visceral leishmaniasis

Canine leishmaniosis and kidney disease: Q&A for an overall management in clinical practice

Contact Info

Product

Resources

About